Multivariate analysis of baseline and time-dependent response features associated with overall survival, event-free survival, and time to myeloma therapy from initiation of protocol treatment
| Variable . | n/N (%) . | Overall survival . | Event-free survival . | Time to myeloma therapy . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Multivariate | |||||||
| B2M 2 mg/L or more | 35/73 (48) | 3.70 (1.30-10.51) | .014† | 1.97 (1.05-3.70) | .035 | 1.30 (0.48-3.55) | .608 |
| Development of CAs* | 1.96 (0.61-6.32) | .259 | 2.06 (1.02-4.15) | .043 | 1.74 (0.60-5.04) | .304 | |
| PR or better response* | 0.92 (0.29-2.99) | .896 | 1.07 (0.54-2.11) | .844 | 4.90 (1.71-14.04) | .003 | |
| Variable . | n/N (%) . | Overall survival . | Event-free survival . | Time to myeloma therapy . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| Multivariate | |||||||
| B2M 2 mg/L or more | 35/73 (48) | 3.70 (1.30-10.51) | .014† | 1.97 (1.05-3.70) | .035 | 1.30 (0.48-3.55) | .608 |
| Development of CAs* | 1.96 (0.61-6.32) | .259 | 2.06 (1.02-4.15) | .043 | 1.74 (0.60-5.04) | .304 | |
| PR or better response* | 0.92 (0.29-2.99) | .896 | 1.07 (0.54-2.11) | .844 | 4.90 (1.71-14.04) | .003 | |
Multivariate analysis included the following variables for consideration: B2M 2 mg/L or higher, Hb less than 120 g/L (12 g/dL), platelets less than 230 × 109/L, development of CA, and PR or better response. Cutoff values for CRP, B2M, albumin, hemoglobin, creatinine, LDH, and platelets were determined using the running log-rank test.
Time-dependent variable.
Statistically significant values are shown in bold.